NVCT insider buying

4 cluster buys

Nuvectis Pharma, Inc. · Healthcare

When two or more insiders at Nuvectis Pharma, Inc. buy NVCT on the open market around the same time, that clustered conviction is one of the highest-signal patterns in SEC filing data. Below is every cluster we've detected in NVCT plus the full record of qualifying open-market buys, each parsed directly from Form 4 filings and linked back to the source on SEC EDGAR.

Clusters
4
Distinct insiders
8
Total bought
$4.4M
Market cap
$524.9M

Detected clusters

  • Jun 30 – Jun 30, 2026
    Detected Jul 1, 2026
    High conviction2 insiders
    Total bought
    $1.2M
    Market cap
    $524.9M
  • Oct 23 – Nov 5, 2025
    Detected Nov 5, 2025
    High conviction4 insiders
    Total bought
    $1.1M
    Market cap
    $618.9M
  • Nov 15, 2024 – Jun 20, 2025
    Detected Jun 20, 2025
    High conviction4 insiders
    Total bought
    $2.1M
    Market cap
    $618.9M

1 more cluster in NVCT

Sign in free to see the full history, or go Pro for real-time alerts the moment new insider clusters form.

All notable open-market buys in NVCT

Every open-market Form 4 purchase, newest first. Click an insider to see their full buying record across companies.

DateInsiderSharesPriceValueFiling
Jun 30, 2026
10% Owner
50,000$18.32$916.0KSEC ↗
Jun 30, 2026
Director, Chairman & CEO, 10% Owner
12,500$20.00$250.0KSEC ↗
Nov 5, 2025
Director
13,000$5.79$75.3KSEC ↗
Nov 5, 2025
Director
11,000$5.84$64.2KSEC ↗
Nov 5, 2025
Director, Chairman & CEO, 10% Owner
5,000$5.72$28.6KSEC ↗
Oct 27, 2025
10% Owner
72,836$6.28$457.4KSEC ↗
Oct 24, 2025
10% Owner
35,034$6.15$215.5KSEC ↗
Oct 23, 2025
10% Owner
46,900$6.06$284.2KSEC ↗
Jun 20, 2025
10% Owner
5,603$7.99$44.8KSEC ↗
Jun 18, 2025
10% Owner
28,043$8.05$225.7KSEC ↗
May 12, 2025
10% Owner
21,167$8.11$171.7KSEC ↗
May 8, 2025
10% Owner
2,400$8.65$20.8KSEC ↗
May 8, 2025
10% Owner
100$8.65$865.0SEC ↗
May 8, 2025
10% Owner
100$8.65$865.0SEC ↗
May 8, 2025
10% Owner
50$8.65$432.5SEC ↗
May 7, 2025
10% Owner
9,614$8.64$83.1KSEC ↗
May 7, 2025
10% Owner
2,703$8.40$22.7KSEC ↗
May 6, 2025
10% Owner
10,104$8.64$87.3KSEC ↗
May 6, 2025
10% Owner
2,340$8.40$19.7KSEC ↗
Feb 7, 2025
10% Owner
240,000$5.00$1.2MSEC ↗
Dec 24, 2024
Director, Chairman & CEO, 10% Owner
4,500$4.65$20.9KSEC ↗
Dec 13, 2024
10% Owner
17,000$4.70$79.9KSEC ↗
Nov 19, 2024
Chief Science & Business Off
2,000$4.99$10.0KSEC ↗
Nov 15, 2024
Director, Chairman & CEO, 10% Owner
20,000$4.92$98.4KSEC ↗
May 14, 2024
Director, Chairman & CEO, 10% Owner
1,940$6.74$13.1KSEC ↗
3 earlier buys hidden — sign in free to see the full history.

More Healthcare stocks with insider cluster buys

All insider buying in Healthcare

NVCT insider buying — FAQ

Are insiders buying NVCT stock?
Yes — 8 distinct insiders have bought NVCT (Nuvectis Pharma, Inc.) on the open market, including 4 cluster buys where two or more insiders bought within a rolling window. The most recent qualifying activity was Jul 1, 2026.
How much NVCT stock have insiders bought?
Insiders have bought a combined $4.4M of NVCT across 28 open-market purchases, based on SEC Form 4 filings.
What is an insider cluster buy in NVCT?
A cluster buy is two or more distinct Nuvectis Pharma, Inc. insiders — officers, directors, or 10% owners — each buying NVCT on the open market within a rolling window. NVCT has 4 detected cluster buys to date.
Where does this NVCT insider trading data come from?
Every figure is parsed directly from SEC Form 4 filings on EDGAR, and each purchase on this page links back to its original filing document.

How we track insider buying in NVCT

We continuously poll SEC EDGAR for new Form 4 filings and parse every open-market purchase (transaction code P). A cluster is recorded when two or more distinct insiders — officers, directors, or 10% owners — each buy NVCT within a rolling window. We track clusters at every company size, from micro-caps to mega-caps. Every figure on this page traces back to an official filing; open any row to jump straight to the source document. What counts as a cluster buy?

This page is informational and reflects public filing data. It is not investment advice or a recommendation regarding NVCT.